(Total Views: 752)
Posted On: 06/14/2017 10:43:18 PM
Post# of 72436
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Correction in bold :
Anybody have any conjectures why Leo is releasing interim 6 week data in quarter 3 and not some preliminary partial like he did with the 19 patient Brilacidin-OM? It would be nice to see something first day of business in July.
Could it be IPIX is bound in a CDA with BPs for Prurisol 2B to only release 6 week interim data when X # of blinded 12 or 16 week outcomes are accessible to Leo and whichever BPs have access to?
Anybody have any conjectures why Leo is releasing interim 6 week data in quarter 3 and not some preliminary partial like he did with the 19 patient Brilacidin-OM? It would be nice to see something first day of business in July.
Could it be IPIX is bound in a CDA with BPs for Prurisol 2B to only release 6 week interim data when X # of blinded 12 or 16 week outcomes are accessible to Leo and whichever BPs have access to?
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)